Is Cabaletta Bio, Inc. (CABA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.1% / 30% | 53.7% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 5.1% / 33% | 53.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 8.4% / 33% | 88.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 5.1% / 33% | 53.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 8.4% / 33% | 88.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -127.0% | |
| Return on Assets (ROA) | -61.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$88M |
| Free Cash Flow | -$90M |
| Total Debt | $16M |
| Debt-to-Equity | 24.2 |
| Current Ratio | 2.8 |
| Total Assets | $185M |
Price & Trading
| Last Close | $2.82 |
| 50-Day MA | $2.90 |
| 200-Day MA | $2.28 |
| Avg Volume | 3.0M |
| Beta | 3.3 |
|
52-Week Range
$0.99
| |
About Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cabaletta Bio, Inc. (CABA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cabaletta Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cabaletta Bio, Inc.'s debt ratio?
Cabaletta Bio, Inc.'s debt ratio is 5.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.4%.
What are Cabaletta Bio, Inc.'s key financial metrics?
Cabaletta Bio, Inc. has a market capitalization of $298M. Return on equity stands at -127.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.